Trials / Completed
CompletedNCT00310635
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 241 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 32 Months – 40 Months
- Healthy volunteers
- Accepted
Summary
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Meningococcal C conjugate vaccine |
Timeline
- Start date
- 2005-06-01
- First posted
- 2006-04-04
- Last updated
- 2006-10-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00310635. Inclusion in this directory is not an endorsement.